This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents: Crizotinib
Indication: Treatment of patients with anaplastic lymphoma kinase-positive (ALK-+) metastatic non-smallcell lung cancer (NSCLC) who were previously treated with crizotinib
Mechanism of action:
ALK tyrosine kinase inhibitor that blocks proteins that promotes the development of cancerous cells 
Ramucirumab -Cyramza (Eli Lilly)
Comparative agents: Bevacizumab
Indication:
Treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fl uoropyrimidine-or platinum-containing chemotherapy
Mechanism of action:
Recombinant monoclonal antibody of the IgG1 class that binds to vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the activation of the receptor that results in a reduction in new blood vessels to the tumor 
Siltuximab -Sylvant injection (Janssen Biotech)

Comparative agents: None
Indication: Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodefi ciency virus-negative (HIV-) and human heres virus-8-negative (HHV-8)
Mechanism of action:
Binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors Volume 49, July-August 2014
Vorapaxar -Zontivity (Merck)
Comparative agents: Warfarin
Indication:
Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Vorapaxar has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).
Mechanism of action:
Protease-activated receptor-1 (PAR-1) antagonist 
